- In March 2024, W. L. Gore & Associates expanded its GORE PROPATEN vascular graft portfolio by introducing a new configuration optimized for hemodialysis access procedures. This product enhancement focuses on reducing the incidence of graft thrombosis and improving long-term patency rates. The development reflects Gore’s commitment to advancing synthetic graft technologies tailored for complex renal access needs, reinforcing its leadership in vascular innovation
- In February 2024, Humacyte, Inc. announced the completion of Phase III clinical trials for its bioengineered Human Acellular Vessel (HAV) designed for hemodialysis access. These vessels, created from human cells and decellularized to prevent immune rejection, showed promising results in terms of durability and infection resistance. This advancement marks a significant milestone in regenerative medicine and could redefine long-term access solutions for ESRD patients pending regulatory approval
- In January 2024, Becton, Dickinson and Company (BD) launched a new version of its AV access graft featuring antimicrobial properties and an improved heparin-bonded surface. Designed to reduce the risks of infection and stenosis, the graft supports better outcomes in patients with repeated access needs. This innovation aligns with BD’s strategic efforts to expand its presence in the vascular access market with differentiated technologies
- In December 2023, Medtronic plc announced a strategic partnership with a network of outpatient dialysis centers in Southeast Asia to pilot its next-generation vascular grafts. The partnership aims to address regional disparities in vascular access care by deploying advanced synthetic grafts with integrated monitoring capabilities. This initiative demonstrates Medtronic’s focus on increasing accessibility and standardizing graft performance across emerging healthcare markets
- In October 2023, LeMaitre Vascular, Inc. acquired Artegraft, Inc., a company specializing in biologic vascular grafts for hemodialysis. The acquisition enhances LeMaitre’s biologic product offerings and expands its customer base in North America. This move underscores a growing industry trend toward consolidating biologic and synthetic graft portfolios to provide comprehensive vascular access solutions for dialysis patients
